Authors: Y. Chen, F. Gao
Affilation: West China Hospital, Sichuan University, China
Pages: 172 - 175
Keywords: uPAR, rhesus monkey, MR imaging, pharmacokinetics
Increasing evidence support the potential of a novel cell surface receptor-targeted MRI nanoprobe produced by conjugating a recombinant peptide amino-terminal fragment (ATF) of urokinase plasminogen activator (uPA) to magnetic iron oxide nanoparticles (IONP) in targeted cancer imaging and therapy. To translate uPAR-targeted human ATF-IONPs into clinical applications, we examined toxicity and pharmacokinetics of uPAR-targeted human ATF-IONPs and the feasibility of non-invasive MRI follow-up of IONPs accumulation in the major organs in rhesus monkeys following systemic delivery.Systemic delivery of 5 mg/Kg of iron equivalent concentration of uPAR-targeted human ATF-INOPs has been shown to be safe in the rhesus monkey. The transient abnormality in serological test of hepatic function was also observed, suggesting that there may be a general side effect caused by uPAR-targeted human ATF-INOPs probes. But the liver function was recovery 3 month after the injection. Therefore, results of our study in monkeys support the potential of future development of uPAR-targeted IONPs as receptor-targeted MRI contrasts as well as theranostic agents for the detection and treatment of human cancers.